Excelestar Ventures
VC Fund
Andover, United States
Excelestar Ventures is a VC fund in Andover focused on Biotechnology and Medical Device. At Excelestar Ventures, they strive to add value to businesses seeking to expand their presence in their industry. From a portfolio perspective, they help portfolio companies realize operational efficiencies to produce growth and sustainable profits. Their team performs extensive market research and conducts consultations with industry experts inits investment due diligence process, through which they are able to secure positions in undervalued companies with proven intrinsic value. Their management approach is hands-on, continuously working with their clients to add real value. As such, Excelestar is selective in its investments in order to yield solid returns for our investors.Since its founding, Excelestar has become a global company invested in mature businesses needing capital to expand operations. They invest globally, understanding that opportunities for success are not limited by borders but made possible through efficient but robust business models. Their success lies in refining and reinvigorating those sound models.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Excelestar Ventures invests in
Stages Excelestar Ventures invests in
Countries Excelestar Ventures invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Tasneem Dohadwala
|
|||
|
Ibrahim Al-Qamari
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 6 (30%)
- Medical Device 6 (30%)
- Medical 4 (20%)
- Health Care 4 (20%)
- Analytics 3 (15%)
Stage
- Series A 5 (25%)
- Series B 4 (20%)
- Seed 3 (15%)
- Series C 2 (10%)
- Series D 2 (10%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tasneem Dohadwala
Founding Partner
|
Founding Partner | Total investments: 3 | Find email | |
|
Ibrahim Al-Qamari
Principal
|
Principal | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Adona Medical
|
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $33.5M / Series C / Jul 10, 2024 | |
Brixton Biosciences
|
Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for pain treatment. Backed by deep research, the company addresses crucial unmet needs in pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, provide painrelief in a single, safe, and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution. | $33M / Series B / May 14, 2024 | |
Instylla
|
Instylla’s focus is to leverage hydrogel technology . | $30M / Series C / Aug 15, 2023 | |
Sealonix
|
Sealonix focuses on the development and commercialization of hemostatic sealants using its proprietary biomaterials. Sealonix is working on a sealant patch that will provide quick hemostasis for abdominopelvic and orthopedic operations. The PramStat patch is intended to bioabsorb within one week of implantation. | $20M / Series A / May 12, 2023 | |
Datacy
|
Datacy is a marketplace enabling ethical and legal data exchange. With Datacy, users can collect and securely hold all their data in one place. Users can control who accesses their data and on what terms, and get paid every time it is used. Datacy uses the latest technology to help users earn from their data, effortlessly. | $5.5M / Seed / Aug 02, 2022 | |
|
Adona Medical
|
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $37.5M / Series B / Apr 29, 2022 | |
Concerto Biosciences
|
Concerto Biosciences discovers and develops specific combinations of microbial ensembles. Using kChip, a patented, high-throughput platform that constructs and screens millions of defined microbial communities - Concerto creates massive data sets on how microbes function when growing in complex communities. From these data, Concerto directlydiscovers microbial ensembles that perform a desired task and learns design rules for ensemble engineering. | $24.5M / Series A / Mar 22, 2022 | |
Chromatic 3D Materials
|
Chromatic 3D Materials is inventing the next generation of 3D printing materials with the durability to meet the requirements for finished manufactured goods. Today, their reality includes infinite possibilities for novel product designs, made possible by their customizable property range. | $4.9M / Venture - Series Unknown / Oct 12, 2021 | |
RoadSync
|
From our beginnings in 2015, RoadSync has been on an upward trajectory, quickly becoming the chosen financial solution for some of the largest names in the logistics space. Our team is standing by, ready to help you with smart, simple, and innovative financial solutions that help you modernize your commerce. RoadSync is on a mission to automatethe financial solutions fueling the $800B logistics industry. | $30M / Series B / Jun 24, 2021 | |
|
Brixton Biosciences
|
Brixton Biosciences is a clinical-stage life sciences company developing novel therapies for pain treatment. Backed by deep research, the company addresses crucial unmet needs in pain management, which has historically been dominated by systemic medicine. Brixton Biosciences' innovative therapeutics, such as its novel Neural Ice™, provide painrelief in a single, safe, and easy drug-free injectable that is a non-addictive, locally targeted, and comparatively long-lasting solution. | Venture - Series Unknown / Jan 01, 2021 | |
| See all 20 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Excelestar Ventures invest in?
Excelestar Ventures invests primarily in Biotechnology, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Excelestar Ventures?
Public channels for Excelestar Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Excelestar Ventures?
The team at Excelestar Ventures includes Tasneem Dohadwala (Founding Partner) and Ibrahim Al-Qamari (Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
